Glycemic Effects and Predictors of Increased Time-in-Range After Initiating MiniMed 670G: A 12-Month Observational Study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Glycemic Effects and Predictors of Increased Time-in-Range After Initiating MiniMed 670G : A 12-Month Observational Study. / Jacobsen, Sabine Schade; Hommel, Eva; Ranjan, Ajenthen G.; Nørgaard, Kirsten.
In: Diabetes Technology & Therapeutics, Vol. 24, No. 8, 2022, p. 592-597.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Glycemic Effects and Predictors of Increased Time-in-Range After Initiating MiniMed 670G
T2 - A 12-Month Observational Study
AU - Jacobsen, Sabine Schade
AU - Hommel, Eva
AU - Ranjan, Ajenthen G.
AU - Nørgaard, Kirsten
PY - 2022
Y1 - 2022
N2 - We aimed to evaluate the glycemic effect and detect any predictors of improved time-in-range (TIR) in persons with type 1 diabetes after initiating hybrid closed-loop (HCL) treatment with MiniMed 670G in a 12-month retrospective observational study. Before starting HCL treatment, the 62 participants followed a Steno-developed training program; 7 participants (6.5%) discontinued the HCL therapy; the remaining 55 (58% female) had an age (mean +/- standard deviation) of 45.6 +/- 12.6 years and diabetes duration of 28.2 +/- 10.9 years. After 12 months' HCL therapy, glycated hemoglobin A1c decreased from 7.4% +0.7% to 7.1% +0.5%, TIR increased from 59.3% +/- 13.5% to 72% +/- 9.3%, time in 54-70 mg/dL (3.0-3.9 mM) decreased from 2.4% +/- 2.0% to 1.4% +/- 1.0%, and time in 180-250 mg/dL (10.0-13.9 mM) decreased from 26.4% +/- 8.3% to 20.8% +/- 5.5%, all P < 0.001. Improvement in TIR was significantly associated with lower total daily insulin dose, higher amount of total carbohydrate, and more time spent in Auto Mode. Our findings support the promising results on glycemic outcomes seen with HCL treatment.
AB - We aimed to evaluate the glycemic effect and detect any predictors of improved time-in-range (TIR) in persons with type 1 diabetes after initiating hybrid closed-loop (HCL) treatment with MiniMed 670G in a 12-month retrospective observational study. Before starting HCL treatment, the 62 participants followed a Steno-developed training program; 7 participants (6.5%) discontinued the HCL therapy; the remaining 55 (58% female) had an age (mean +/- standard deviation) of 45.6 +/- 12.6 years and diabetes duration of 28.2 +/- 10.9 years. After 12 months' HCL therapy, glycated hemoglobin A1c decreased from 7.4% +0.7% to 7.1% +0.5%, TIR increased from 59.3% +/- 13.5% to 72% +/- 9.3%, time in 54-70 mg/dL (3.0-3.9 mM) decreased from 2.4% +/- 2.0% to 1.4% +/- 1.0%, and time in 180-250 mg/dL (10.0-13.9 mM) decreased from 26.4% +/- 8.3% to 20.8% +/- 5.5%, all P < 0.001. Improvement in TIR was significantly associated with lower total daily insulin dose, higher amount of total carbohydrate, and more time spent in Auto Mode. Our findings support the promising results on glycemic outcomes seen with HCL treatment.
KW - Hybrid closed-loop
KW - Type 1 diabetes
KW - MiniMed 670G
KW - Training
KW - HYBRID CLOSED-LOOP
KW - INSULIN DELIVERY-SYSTEM
KW - ADULTS
KW - ADOLESCENTS
KW - THERAPY
KW - PUMP
U2 - 10.1089/dia.2021.0532
DO - 10.1089/dia.2021.0532
M3 - Journal article
C2 - 35099298
VL - 24
SP - 592
EP - 597
JO - Diabetes Technology & Therapeutics
JF - Diabetes Technology & Therapeutics
SN - 1520-9156
IS - 8
ER -
ID: 325888857